VAL-083: An Important Biological Approach to Fighting Drug-Resistant Tumors
Demonstrating Potency in Clinical Trials
VAL-083 has been evaluated in more than 40 Phase I and Phase II clinical trials by the U.S. National Cancer Institute and was found to have anti-cancer activities against various cancers, including brain tumors and ovarian cancers.
Glioblastoma (GBM) is the most common and lethal form of brain cancer. As a unique small molecule therapeutic, VAL-083 can potentially offer a new paradigm in the treatment of GBM. Glioblastoma
Pediatric Brain Tumors
Children with high grade glioma have very limited treatment options. VAL-083 has demonstrated promising activities in the treatment of pediatric brain tumors in NCI clinical trials and our recent preclinical studies, supporting future clinical evaluation. Pediatric Cancer
Our research supports VAL-083's potential as a new therapeutic option for platinum-resistant ovarian cancer patients whose treatment is underserved by currently available therapy. Ovarian Cancer
Our Platform Strategy: Unleashing the Potential of Biology
Our drug development strategy is built on a robust understanding of cancer biology. We use modern scientific approaches to determine where we can solve problems for specific tumor types.
Our team is identifying opportunities where a modernized understanding of the anti-cancer mechanism of VAL-083 suggests that this agent can address an unmet need. By showing that VAL-083 is active where others fail, we can demonstrate that our therapies may have the ability to improve patient survival and quality of life.
Explore Our Scientific Publications & Presentations
Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations. View Publications and Presentations